Evidence map›Paper›PMID 37278857›Full record

ReviewWiener klinische Wochenschrift2024

The three pillars in treating antibody-mediated encephalitis.

S Macher, G Bsteh, E Pataraia, T Berger, R Höftberger, P S Rommer

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Wiener klinische Wochenschrift, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

S MacherDepartment of Neurology, Medical University of Vienna, Vienna, Austria.
G BstehDepartment of Neurology, Medical University of Vienna, Vienna, Austria.
E PataraiaDepartment of Neurology, Medical University of Vienna, Vienna, Austria.
T BergerDepartment of Neurology, Medical University of Vienna, Vienna, Austria.
R HöftbergerDepartment of Neurology, Medical University of Vienna, Vienna, Austria.
P S RommerDepartment of Neurology, Medical University of Vienna, Vienna, Austria. paulus.rommer@meduniwien.ac.at.ORCID http://orcid.org/0000-0001-5209-6647
Medical University of Vienna · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The rapid initiation of immunotherapy has a decisive impact on the course of the disease in patients with antibody-mediated encephalitis (AE). The importance of treating AE with antiseizure medication and antipsychotics is discussed controversially; however, standardized procedures should be ensured, especially for the initiation of treatment in severe disease. Recommendations and guidelines for further interventions in refractory courses are needed. In this review, we contrast the three mainstays of treatment options in patients with AE and attempt to highlight the importance of 1) antiseizure therapy, 2) antipsychotic therapy, and 3) immunotherapy/tumor resection from today's perspective.

Indexed as

Autoimmune Diseases of the Nervous SystemImmunotherapyHumansAntineuronal antibodiesAntipsychoticsAutoimmune encephalitisEpilepsyImmunotherapy

Identifiers

PMID37278857
PMCPMC10776469
OpenAlexW4379508646

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.